Cargando…

Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism

BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damag...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowitz, Daniel, Ha, Grace, Ruggieri, Rosamaria, Symons, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703169/
https://www.ncbi.nlm.nih.gov/pubmed/29200877
http://dx.doi.org/10.2147/OTT.S143096
_version_ 1783281652409040896
author Markowitz, Daniel
Ha, Grace
Ruggieri, Rosamaria
Symons, Marc
author_facet Markowitz, Daniel
Ha, Grace
Ruggieri, Rosamaria
Symons, Marc
author_sort Markowitz, Daniel
collection PubMed
description BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, however, have yet to demonstrate the functional consequences of interfering with interphase microtubules in the presence of IR. To address this, we combined IR with an established MTA, mebendazole (MBZ), to treat glioma cells exclusively during interphase. MATERIALS AND METHODS: To test whether MTAs can sensitize interphase cells to IR, we treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation studies were conducted following treatment of glioma cells with MBZ. RESULTS: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm. CONCLUSION: This study demonstrates that MBZ can sensitize cancer cells to IR independently of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into the nucleus.
format Online
Article
Text
id pubmed-5703169
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57031692017-11-30 Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism Markowitz, Daniel Ha, Grace Ruggieri, Rosamaria Symons, Marc Onco Targets Ther Original Research BACKGROUND: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, however, have yet to demonstrate the functional consequences of interfering with interphase microtubules in the presence of IR. To address this, we combined IR with an established MTA, mebendazole (MBZ), to treat glioma cells exclusively during interphase. MATERIALS AND METHODS: To test whether MTAs can sensitize interphase cells to IR, we treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation studies were conducted following treatment of glioma cells with MBZ. RESULTS: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm. CONCLUSION: This study demonstrates that MBZ can sensitize cancer cells to IR independently of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into the nucleus. Dove Medical Press 2017-11-24 /pmc/articles/PMC5703169/ /pubmed/29200877 http://dx.doi.org/10.2147/OTT.S143096 Text en © 2017 Markowitz et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Markowitz, Daniel
Ha, Grace
Ruggieri, Rosamaria
Symons, Marc
Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title_full Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title_fullStr Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title_full_unstemmed Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title_short Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
title_sort microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703169/
https://www.ncbi.nlm.nih.gov/pubmed/29200877
http://dx.doi.org/10.2147/OTT.S143096
work_keys_str_mv AT markowitzdaniel microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism
AT hagrace microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism
AT ruggierirosamaria microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism
AT symonsmarc microtubuletargetingagentscansensitizecancercellstoionizingradiationbyaninterphasebasedmechanism